Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Transplantation tolerance is a continuing therapeutic goal, and it is now clear that a subpopulation of T cells with regulatory activity (Treg) that express the transcription factor foxp3 are crucial to this aspiration. Although reprogramming of the immune system to donor-specific transplantation tolerance can be readily achieved in adult mouse models, it has yet to be successfully translated in human clinical practice. This requires that we understand the fundamental mechanisms by which donor antigen-specific Treg are induced and function to maintain tolerance, so that we can target therapies to enhance rather than impede these regulatory processes. Our current understanding is that Treg act via numerous molecular mechanisms, and critical underlying components such as mTOR inhibition, are only now emerging.

Original publication

DOI

10.1101/cshperspect.a015545

Type

Journal article

Journal

Cold Spring Harb Perspect Med

Publication Date

01/06/2013

Volume

3

Keywords

Animals, Autoimmunity, Biomarkers, Epigenomics, Forkhead Transcription Factors, Graft Rejection, Graft vs Host Disease, Humans, Immune Tolerance, Immunity, Heterologous, T-Lymphocytes, Regulatory, Transcription Factors, Transplantation Tolerance